Biotechnology Symposium: Antibody Expression in E. Coli

Virtual

E. coli is a common platform for recombinant protein expression. An interesting observation regarding translation initiation was made while expressing an antibody. Presented by Zvi Kelman, Director BL2, NIST.

Advocacy in Action: Bystander Intervention

Virtual

Please join us for an interactive session on Bystander Intervention where we will unpack the intersections of violence and reflect on how this impacts our likelihood to intervene in harmful situations. Participants will also learn bystander intervention techniques, also known as the 5 D’s, and reflect on when and how each method might be right for you. This workshop is inclusive of all gender identities, sexual orientations, and is a safe, judgement-free zone.

Biotechnology Symposium: Many Rivers to Cross: The Companies, Connections & Careers Needed for Producing mRNA Vaccines

Virtual

When we read about vaccines in the news, it sounds like a handful of companies are doing everything. As it often happens, the real story is more complicated. Both the Moderna and Pfizer-BioNTech COVID-19 vaccines rely on large networks of suppliers and manufacturers for successfully producing, tracking, and distributing doses. In this talk, we’ll follow the path and explore the different careers for the people and companies working to protect us from COVID-19.

Advocacy in Action: Healthy Relationships

Virtual

Please join us for an interactive session on Healthy Relationships where we will break down healthy and unhealthy relationship behaviors to look out for, as well as an interactive self-reflection activity. This workshop is inclusive of all gender identities, sexual orientations, and is a safe, judgement-free zone.

Biotechnology Symposium: Rapid Development and Manufacturing of Vaccines

Virtual

FDA’s current regulatory framework assures highest safety standards for vaccines but drives a vaccine development to commercial delivery timeline of on average of 6-7 years from initial clinical study start. Some extraordinary events such as bioterrorism threats or pandemics can expedite the process. The speaker will discuss real-world experience with urgent development and stockpile of the smallpox vaccine.